New start-up company offers alternative treatment for cardiovascular disease
Angiograft, co-founded by Stelios Andreadis, Sindhu Row (shown
above) and Daniel Swartz, is developing a way to make
artiﬁcial blood vessels for people with heart disease that
could help reduce the costs associated with coronary bypass
By Jane Stoyle Welch
In the United States, 350,000 coronary artery bypass
grafting procedures are performed annually, costing $26 billion in
health care expenses. Two thirds of the cost comes from secondary
contributors, such as extended hospital stays and readmissions
resulting from donor site complications.
Angiograft LLC, a new company out of the University at
Buffalo’s Department of Chemical and Biological Engineering,
seeks to reduce these costs by making bioengineered blood vessels
for people with heart disease.
Sindhu Row, who earned her PhD in chemical engineering in
February 2016, together with her advisor, Stelios Andreadis,
professor and chair of the Department of Chemical and Biological
Engineering, and Daniel D. Swartz, an expert in blood vessel
grafting, surgery and pediatrics, are moving the product forward
with clinical trials.
“The product is a self-regenerating blood vessel,
available off the shelf, that once implanted, is capable of
regenerating with the patients’ own cells making it
biologically functional,” said Row.
“The acellular technology employs covalent chemistry to
fortify the collagenous grafts with anti-clotting factors as well
as growth factors, which attract the patients’ own cells to
graft site. This enables A-TEV (acellular tissue engineered
vessel) to be manufactured within just one day, and be available
off the shelf, a tremendous advantage for clinical
applications,” she continued.
The company’s A-TEV is designed as a replacement vascular
graft, which is often required in coronary artery bypass grafting
procedures. These procedures typically use the patient’s own
veins; however, people with conditions such as diabetes and
hypertension often do not have viable veins and are thus unable to
undergo the surgery. The technology could, therefore, offer these
patients an alternative through its unique design.
The technology and product are protected under a provisional
patent (62/254,347) with intellectual property rights belonging to
The team was recently among 80 semi- finalists in the 2016
OneStart competition, the world’s largest accelerator for
startups that seek to improve human health. They were selected from
a pool of 750 startups from over 50 countries.
They were also finalists in UB’s Henry A. Panasci Jr.
Technology Entrepreneurship Competition and Bright Buffalo
Niagara’s Entrepreneur Expo. More recently, Angiograft was
named one of 142 semifinalists in 43North, a $5 million startup
competition held in Buffalo, New York.